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Abstract
INTRODUCTION—The overall goal of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
is to validate biomarkers for Alzheimer’s disease (AD) clinical trials. ADNI-3, beginning August 
1, 2016, is a five year renewal of the current ADNI-2 study.
METHODS—ADNI-3 will follow current and additional subjects with normal cognition, mild 
cognitive impairment (MCI) and AD using innovative technologies such as tau imaging, magnetic 
resonance imaging (MRI) sequences for connectivity analyses, and a highly-automated 
immunoassay platform and mass spectroscopy approach for CSF biomarker analysis. A Systems 
Biology/Pathway approach will be used to identify genetic factors for subject selection/
enrichment. Amyloid positron emission tomography (PET) scanning will be standardized using by 
the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject 
cognition.
RESULTS—Multi-modal analyses will provide insight into AD pathophysiology and disease 
progression.
DISCUSSION—ADNI-3 will aim to inform AD treatment trials and facilitate development of 
AD disease-modifying treatments.
Keywords
Alzheimer’s disease; tau imaging; amyloid phenotyping; Centiloid method; Brain Health Registry; 
functional connectivity; clinical trial biomarkers
1. Introduction
The number of Americans with Alzheimer’s disease (AD) is projected to increase from 5.2 
million in 2016 to 13.8 million in 2050 [1]. On the current trajectory, the total cost for AD 
and other dementias during this time is predicted to rise from $236 billion in 2015 to more 
than $1 trillion in 2050 [1]. The Alzheimer’s Association estimates that a treatment that 
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delays the onset of AD by five years would save an estimated $935 billion in just the first 10 
years. Indeed, the ~30% reductions in AD incidence in people >60 with a high school 
education reported from the Framingham study [2] are estimated to have resulted in >$300 
M in health care cost savings. The Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
was launched in 2004 with overarching aims of validating biomarkers for, and informing the 
design of, therapeutic trials in AD [3]. Funded by a unique public–private partnership, ADNI 
has now been running for 12 years, studying subjects with AD dementia (AD) and amnestic 
mild cognitive impairment (MCI), and cognitively normal (CN) elders. Beginning with an 
initial five-year study termed ADNI-1 [4], followed by a two-year extension which enrolled 
early MCI subjects, termed ADNI-GO, and then by a further five-year competitive renewal 
termed ADNI-2 [5]. Over this time, ADNI has made a profound impact on nearly all aspects 
of AD pathobiology and patient oriented research [6]. A five-year competitive renewal of 
ADNI-2, termed ADNI-3, will begin on August 1, 2016. ADNI has been the subject of 
several journal Special Issues [7–9], has generated over 1000 publications, and has been the 
subject of many iterative reviews of its progress and major milestones [3, 10, 11].
ADNI has played and continues to play a central role in improving treatment trials. The 
development of AD therapeutics has stalled in efforts to move beyond modestly effective 
symptomatic drugs, which are likely to have an impact at the dementia stage, to disease-
modifiers, requiring treatment at earlier pre-dementia or even presymptomatic stages of 
disease. There are many reasons for this failure, including issues of target selection, off-
target toxicity, subject selection, and insufficient pharmacokinetic and pharmacodynamics 
data to support trial design. In the past, AD and MCI were diagnosed clinically. 
Unfortunately, the clinical diagnosis lacked specificity (some patients diagnosed with MCI 
or dementia due to AD did not have AD pathology) and sensitivity (it is not possibly to 
identify cognitively normal subjects who have amyloid pathology using clinical 
measurements). One of the major accomplishments of ADNI has been to validate amyloid 
phenotyping, which detects the presence of β-amyloid (Aβ) pathology in living subjects 
with amyloid positron emission tomography (PET) [12–14] and cerebrospinal fluid (CSF) 
measures of Aβ [15–17]. In the past, subjects with clinical AD but without AD pathology 
have likely been enrolled in trials due to lack of amyloid phenotyping [18–20]. This has now 
changed, in part due to the contributions of ADNI. ADNI investigators have advanced the 
design of pre-dementia trials in the statistical [21–24], methodological [25–34], cognitive 
[35] and clinical [31, 32, 36, 37] literature, and with regulators [25] in the US and abroad 
facilitating the design of major completed and ongoing trials (avagacestat, gantanerumab, 
aducanumab, solanezumab, Anti Amyloid Treatment in Asymptomatic Alzheimer’s Disease 
(A4) study, and A5 study). These advances have included the move from time-to-endpoint 
designs to continuous outcome measures as primaries [21, 25], the use of biomarker-based 
subject selection [22], single primary outcomes in prodromal trials [25], and cognitive 
endpoints in pre-dementia clinical trials [38–41].
Current clinical trials use measures of memory, cognition, and/or function as outcomes. 
These are imperfect measures as they are subject to high test-retest variability and are 
influenced by factors other than changes due to AD. A ‘biological marker’ that represents 
progression of AD pathology, correlates with symptomatology (especially memory and 
cognitive decline), and is not affected by non-AD pathology could be used as a surrogate 
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outcome measure, overcoming the problems associated with the current clinical measures. 
Despite some early hopes, brain Aβ burden, measured with amyloid PET or in CSF, does not 
correlate well with disease severity and has not yet been proven an effective surrogate 
outcome [42, 43]. Several counterintuitive results in which increased brain atrophy was 
reported in response to anti-Aβ therapy [44–49] have also ruled out volumetric magnetic 
resonance imaging (MRI) measures as satisfactory surrogate markers for therapeutic Aβ 
reduction. However, MR measures may still be a highly useful outcome measure for 
neuroprotective interventions. What therefore might be the ideal surrogate outcome 
measure? Pathological studies have indicated that AD symptomatology is more closely 
associated with tau tangles than Aβ deposits [43, 50, 51], and that brain tau correlates with 
cognition [43, 50, 51], suggesting a cause-effect relationship between tau tangles, synaptic 
dysfunction/synapse loss/neurodegeneration, and cognitive function. Recently, [18F]-T807 
(also known as AV1451) and other tau PET ligands have been developed to detect tau in 
humans [52], raising the possibility that tau PET could ultimately be used as a surrogate 
marker for AD clinical trials. However, synaptic loss correlates most closely with cognitive 
impairment in AD so it is likely that CSF synaptic protein biomarkers such as neurogranin 
could play a significant role as a surrogate marker in concert with biomarkers of AD 
pathology [53].
ADNI-3 aims to directly improve clinical trials in four major ways. Firstly, it will study the 
use of tau PET for subject selection, as a baseline covariate and as a potential surrogate 
outcome measure. Secondly, it will investigate other signals such as change in CSF 
biomarkers, and functional imaging techniques ([18F]-fluorodeoxyglucose-PET (FDG-PET), 
arterial spin labelling perfusion (ASL) MRI, and task-free functional MRI (TF-fMRI) that 
may detect treatment effects in phase 2 trials. [54]. Thirdly, it will directly address the lack 
of reliability of Aβ and tau phenotyping through the standardization of different amyloid 
PET tracers in the ‘Centiloid project’, and the development of new immunoassay platforms 
and mass spectroscopy techniques to improve the reliability of CSF analysis of Aβ and tau 
as well as assess the utility of CSF synaptic protein biomarkers such as neurogranin [55]. 
Lastly, in conjunction with the Brain Health Registry (BHR; www.brainhealthregistry.org 
[56]), it will implement web-based methods for recruitment and characterization of subjects 
to overcome the problems of slow recruitment, and high trial costs due to high “screen fails”.
A secondary goal of ADNI-3 is to deepen our understanding of the progression and 
pathophysiology of AD. Continuation of the longitudinal phenotyping of AD from 
preclinical to prodromal to dementia stages will provide further insight into the disease 
process. Tau PET studies will investigate the relationship between Aβ and tau across the 
spectrum of cognition. The provision of biofluid samples to outside ‘omics’ projects such as 
lipidomics and metabolomics [57, 58] will facilitate a Systems biology/Pathway analysis 
approach to characterizing AD. Improvement of methods for measuring functional and 
structural connectivity using MRI ‘Connectome-like’ sequences will provide insight into the 
role of connectivity in this disease. Finally, ADNI-3 will continue to serve three Department 
of Defense ADNI grants investigating the relationship of traumatic brain injury and post-
traumatic stress disorder on development of AD in Vietnam Veterans [59].
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Given that ADNI has had a myriad of impacts on diverse aspects of AD [6] and in fields 
beyond the mandate of the Initiative, and that these impacts continue to multiply with the 
growing pool of shared data, is expected that ADNI-3 will make even greater inroads into 
enabling successful clinical trials of AD therapies and that its multimodal, longitudinal 
approach will provide important insights into disease progression.
2. Methods
2.1 Study design
ADNI-3 will be a continuation of ADNI-2, and is projected to retain 697 subjects from 
ADNI-2 (295 CNCN274 amnestic MCI, and 128 AD). To provide sufficient power and 
compensate for loss of drop outs, ADNI-3 will enroll an additional 133 CN (with and 
without the subjective memory concerns), 151 amnestic MCI (both early and late MCI) and 
87 AD subjects (371 total new subjects) which will result in a cohort with 40% CN, 40% 
MCI and 20% AD subjects (Table 1). The BHR, an innovative internet-based registry for 
recruitment, assessment, and longitudinal monitoring for neuroscience studies, will be used 
for the identification and screening of eligible ADNI-3 participants, and for subsequent 
cognitive longitudinal monitoring using online neuropsychological tests. Enrollment is 
expected to be completed in 2017. There will be 3–4 years of follow-up for all newly 
enrolled subjects. MCI and AD subjects will be seen every year for a clinical visit and MRI. 
Most CN subjects will be seen on alternating years for clinical visits and phone checks 
although some CN subjects selected to receive a tau PET will have annual clinical visits. All 
MCI and CN subjects will receive a tau PET scan at baseline and in Year 5. Amyloid 
positive subjects may be randomly selected to receive two additional tau PET scans on the 
basis that Aβ level correlates with the level of brain tau tangles. AD subjects will receive a 
tau PET scan every year. All subjects receive amyloid PET and lumbar punctures every other 
year. MCI and AD subjects will receive a FDG-PET scan at baseline. CN and MCI subjects 
will be followed through the entire project while AD subjects will be followed for 24 
months.
2.2 Clinical Core
The Clinical Core/Coordinating Center, led by Paul Aisen and Ronald Petersen, will 
continue to be responsible for managing the day-to-day clinical operations of ADNI, 
including the retention and follow-up of ADNI-2 subjects, and the enrolment of new 
subjects. Most clinical assessments from ADNI-2 will be continued in ADNI-3 to preserve 
the value of the longitudinal dataset. The proprietary Boston Naming Test will be replaced 
with the license-free Multilingual Naming Test [60]. The Core will also incorporate a 
performance-based functional assessment, the Financial Capacity Instrument.-Short Form 
[61].
The BHR will be used to assist recruitment of new enrollees and for at home longitudinal 
monitoring. Like the BHR, ADNI-3 will use theweb-based computerized cognitive 
assessment, CogState, which may be more sensitive early in the disease course, is simple to 
perform, culture free, and exhibits minimal learning effects [62, 63]. BHR currently has over 
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40,000 participants, 37% of whom are over age 55 and report memory concerns, and 29% of 
whom endorse a first degree relative with dementia.
2.3 PET Core
The PET Core, led by William Jagust, will establish harmonized protocols for the collection 
of tau PET and amyloid PET data, quality control of all acquired data, and data analysis. 
Florbetaben (Neuraceq) [64] will be incorporated as a second amyloid tracer in addition to 
florbetapir. Those subjects from ADNI-2 will continue to be evaluated with [18F]florbetapir 
whereas new subjects enrolled in ADNI-3 will be evaluated with longitudinal 
[18F]florbetaben. Tau PET data acquired using the tau ligand [18F]T807 will be examined 
using region-of-interest based approaches that recapitulate Braak staging in order to define 
tracer uptake by topography. The Banner Alzheimer Institute will examine whole-brain 
voxelwise approaches to tau PET data and will calculate a cerebral tau index to define extent 
and magnitude of brain tau deposition. The PET Core will continue FDG-PET imaging at 
the baseline examination on all subjects. Multimodal analysis including all PET and MRI 
data will form the basis for testing a proposed set of hypotheses that examine the ability of 
different PET biomarkers to predict outcomes at different stages of the AD 
pathophysiological process, how the biomarkers relate to one another, and how changes in 
biomarkers are related to clinical change.
2.3.1. Centiloid scale for the comparison of amyloid PET tracers—To allow 
direct comparison of amyloid tracers ([18F]florbetapir, [18F]florbetaben, [11C]Pittsburgh 
Compound (PiB)), regional brain standardized uptake value (SUV) outcomes will be 
converted into Centiloids, a process that reports amyloid tracer retention on a 0–100 scale 
using [11C]PIB as a reference. We hypothesize that different amyloid imaging agents will 
have similar effect sizes for prediction of decline and detection of longitudinal change when 
placed on the Centiloid scale. Combining different amyloid imaging agents on this scale will 
increase statistical power.
2.3.2. Tau imaging—A major feature of ADNI-3 is the incorporation of multisite, 
longitudinal tau PET imaging, which, in conjunction with clinical/cognitive assessments 
amyloid PET, MRI, CSF analysis, genetics, and widespread data sharing is expected to make 
a substantial contribution to our understanding of the role of tau in AD pathophysiology. 
Previous exploratory work using both region of interest (ROI) and voxel-based approaches 
have suggested a correlation between tau and cognition. In the ROI approach, patients were 
classified according to Braak staging determined by T1 MRI scan. Higher PIB retention and 
smaller hippocampal volumes were significantly associated with higher Braak stages even 
excluding those subjects with manifest clinical AD. There was a strong correlation (β=
−3.191, p = .008) between performance on a standard laboratory episodic memory factor 
score and retention of [18F]T807 in Braak stage 1/2 ROIs, and between global cognition and 
[18F]T807 retention in Braak stage 3/4 and 5/6 ROIs (Figure 1) [65]. Voxelwise analysis 
using a cerebral tau index (CTI) differentiated between patient groups and young controls. In 
these data, CTI also correlated with the Mini Mental State Exam (MMSE) (r=.558 p=.016 in 
old controls, MCI, AD).
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2.4 MRI Core
The MRI Core, led by Clifford Jack, will continue to improve clinical trials by developing 
and standardizing protocols, operationalizing definitions of clinical subgroups to 
accommodate biological heterogeneity, and optimizing inclusion/stratification and outcome 
metrics. ADNI-2 acquisition protocols will be expanded in ADNI-3 to include seven 
sequences (structural MRI, FLAIR and T2*GRE, diffusion MRI (dMRI), TF-fMRI, ASL 
perfusion MRI, and a high resolution coronal T2 fast spin echo) in all subjects. In addition, 
the dMRI and TF-fMRI protocols will be implemented using both standard and advanced 
protocols. The advanced dMRI and TF-fMRI acquisitions will be implemented on systems 
that are capable and will resemble those performed in the Human Connectome Project 
(HCP). ADNI-3 will be the largest multi-site, multi-vendor study to leverage several 
advanced MRI methods. HCP-like dMRI will offer more precise region-based fractional 
anisotropy and mean diffusivity measures as well as higher-fidelity characterization of white 
matter tract geometry. HCP-like TF-fMRI acquisitions will offer many advantages over 
standard TF-fMRI, including greater temporal and spatial resolution, less noisy connectivity 
measures, and time-varying connectivity. ASL perfusion MRI in ADNI-3 will be acquired 
using the 3D Pseudo-Continuous ASL protocol recommended by the International Society 
for Magnetic Resonance in Medicine perfusion work group, on systems where this is 
possiblee. High-resolution medial temporal lobe (MTL) subregion imaging offers 
quantification of changes in hippocampal subfields and parahippocampal gyrus subregions, 
which are the location of the earliest stages of tau pathology [66–69]. All ADNI-3 scans will 
be acquired at 3T.
2.5 Biomarker Core
The Biomarker Core, led by Leslie Shaw and John Trojanowski, will continue the ADNI 
Biofluid Biobank and distribution of samples to investigators, provide highly standardized 
Aβ1–42, t-tau and p-tau181 measurements on CSF samples, collaborate in the development of 
new tests for blood biomarkers (eg, ApoE4 protein in plasma; t-tau in plasma; exosomal 
fraction) and CSF biomarkers that detect co-pathologies such as Lewy Bodies and TDP43 
proteinopathy in addition to other informative CSF proteins such as neurogranin.
Previously, the Core found close agreement in the measurement of CSF Aβ1–42 with a co-
developed reference method that uses the same sample preparation steps but different HPLC 
and mass spectrometry instrumentation (Figure 2). An effort involving four laboratories in 
the Alzheimer’s Association (AA) Global Biomarker Standardization Consortium (GBSC) 
showed very good concordance across 12 CSF pool samples (R2=0.98; average intra-
laboratory %CV of 4.7%; inter-laboratory %CV of 12.2%) that improved further when 
adjusted using a common calibrator[70]. Validation efforts for the fully-automated accuracy- 
and precision-based Roche Elecsys immunoassay platform for the measurement of Aβ1–42, 
t-tau and p-tau181 in all ADNI CSF samples are ongoing. One study over multiple centers 
has been completed and suggests that this method shows the best inter-laboratory 
performance reported for any method to date: the total measurement error across four 
participating laboratories and three different reagent lots and across five days of runs ranged 
from 2.2 to 5.1% over the five different CSF pools used for this study [71]. This system will 
be fully implemented in ADNI-3. In addition, a newly validated mass spectrometry assay for 
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Aβ1–42, Aβ1–40 and Aβ1–38 using a 2D-UPLC/MS-MS platform [55, 72], calibrated with a 
surrogate calibrator matrix prepared from artificial CSF plus 4 mg/mL bovine serum 
albumin, will be implemented in all ADNI-3 CSF samples. A mass spectrometry-based 
measurement of t-tau using a high sensitivity MRM mass spectrometry system will be 
validated and implemented for t-tau measurement in CSF of all ADNI-2 and ADNI-3 study 
subjects.
Using these improved methods of measurement, we predict that the CSF biomarkers alone 
and in combination for subject selection will reduce sample sizes thus improving efficiency 
for treatment trials, and that pathologic concentrations of Aβ1–42 will predict decline in 
measures of memory, cognition and function. Furthermore, we hypothesize that rates of 
change of CSF Aβ1–42 will be predictive of decline in memory, cognition, and function and 
ADNI-3 subjects.
2.6 Genetics Core
The Genetics Core, led by Andrew Saykin, will continue to provide genomic biosample 
banking and genotyping, identify and validate genetic markers to enhance clinical trial 
design and drug discovery, and provide an organizational framework to foster collaboration 
on genomic studies within ADNI-3. In addition to protocols employed in ADNI-2, 
peripheral blood mononuclear cells will be banked for use in development of induced 
pluripotent stem cells, functional drug development-related assays and other purposes. 
Systems biology modeling approaches yielding polygenic risk scores and gene pathway- and 
network-based metrics will be used to predict disease progression and outcomes. 
Associations between variation in the MAPT gene, encoding tau protein, and other 
pathways, and tau PET will be investigated and the influence of genetic variation on 
proteomics and metabolomics biomarker assays will be assessed.
We anticipate that ADNI data will demonstrate that the efficiency of clinical trials can be 
improved by enrichment with genetic markers beyond APOE, thereby reducing sample size, 
time required to complete trials, and lowering costs. Beginning with AD candidate genes 
nominated by large genome wide association studies (GWAS) [73] sequencing studies (e.g., 
TREM2 [56–59], PLD3 [60]), prior studies of AD endophenotypes in ADNI [74, 75] and 
other studies, followed by GWA (e.g., [76, 77]), we expect to identify variants that improve 
prediction of disease trajectory (i.e., onset, course, and outcome). We also predict that 
variants associated with biomarkers may yield clues to biological mechanisms and serve as 
potential targets for enrichment or therapeutic development. Examples of candidate trial 
enrichment markers that will be further studied in ADNI-3 include BCHE [76] and IL1RAP 
[78]. Additional data generated by ADNI-3 will enhance power by increasing participants 
with complete longitudinal data (and the range of phenotypes).
We envision that the innovative Systems Biology modeling approaches yielding polygenic 
risk scores and gene pathway- and network-based metrics will prove more powerful than 
single variants in predicting disease progression and outcomes, and that variation in the 
MAPT gene and other pathways will be associated with tau PET. Finally, we predict that 
controlling for the influence of genetic variation on proteomics (from studies of ADNI 
plasma and CSF samples) and metabolomics (through collaboration with the AD 
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Metabolomics Consortium), biomarker assays will improve the performance of –omics 
biomarkers in predicting disease progression and outcomes.
2.7 Neuropathology Core
The Neuropathology Core, led by John Morris and Nigel Cairns, will continue to foster and 
facilitate a voluntary brain autopsy for each ADNI participant at each site, to maintain a 
repository of frozen and fixed brain tissue from ADNI participants, and to validate the 
clinical, CSF biomarker and neuroimaging data of participants collected during the period of 
the grant. Additionally in ADNI-3, the contribution of common comorbidities (Lewy bodies, 
TDP-43 proteinopathy, vascular disease, hippocampal sclerosis, and tau astrogliopathy) to 
the variance in clinical, CSF biomarker, and neuroimaging data will be investigated, and the 
relationships between neuropathology and genomic data in multimodal studies of ADNI 
participants will be characterized. In participants who have undergone tau PET imaging, the 
spatial organization of tau burden in the postmortem brain will be correlated with tau PET 
data in collaboration with the PET Core.
Since the inception of the ADNI Neuropathology Core, the overall autopsy rate (number of 
autopsies/number of deaths) is 62%, with tissue received from 49 of the 52 patients who 
have come to autopsy at one of the ADNI sites. Currently, 42 of 57 ADNI-2 sites are fully 
operational to obtain autopsy consent and brain donation and we anticipate that during 
ADNI-3, a number of additional sites will become operational. Thus far, nearly half (18/41) 
of autopsied patients diagnosed with documented plaque and tangle AD pathology also had 
some form of comorbidity, most commonly Lewy bodies (synucleinopathy) and TDP-43 
proteinopathy in the medial temporal lobe as well as argyrophilic grain disease and 
hippocampal sclerosis. We hypothesize that these comorbidities contribute to the variance in 
clinical, CSF biomarker, and neuroimaging data. By obtaining at least 100 total brains by the 
end of the next grant cycle, we calculate we will have 80% power to detect a correlation 
coefficient accounting for 8% of variation (r = ±0.28). We expect to gain insight into the 
relationship between these comorbidities and genetics using comprehensive integrative 
genomics and bioinformatics analyses with ADNI genome sequencing data in collaboration 
with the Genetics Core. We hypothesize that tau PET will be a better predictor of cognitive 
decline than other imaging and CSF biomarkers.
2.8 Biostatistics Core
The Biostatistics Core, led by Laurel Beckett, will carry out analyses of ADNI-3 data, 
separately, and in combination with data from previous phases with the aim of validating the 
potential of key clinical, functional, MRI, PET, CSF, and genetic biomarkers. Baseline 
biomarker distribution and performance, and longitudinal biomarker change will both be 
characterized as predictors of cognitive, functional, and biological change, of progression 
from CN to MCI and MCI to AD, and for use as inclusion/exclusion criteria, screening and 
stratification. New biostatistical methodologies will be developed to support ADNI-3 goals 
including those that account for missing and/or skipped data. A model for disease 
progression [79] will be extended to include tau PET data and to capture heterogeneity 
among sub-populations in the order of marker progression. Generalized Mallows models 
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will be extended to estimate the most likely sequence of progression events and its variation 
within and between sub-populations.
By combining results from PET tracers for amyloid, tau, and metabolism (FDG), and other 
measures, we predict that metabolism and tau, but not amyloid, will be correlated with 
cognition, and that metabolism will be negatively correlated with tau, but not correlated with 
amyloid. Moreover, we hypothesize that longitudinal changes in tau will be most strongly 
related to cognitive decline in all subject groups, whereas amyloid and metabolism will be 
very weakly related, and moderately related, respectively, to longitudinal cognitive decline. 
We hypothesize that future cognitive decline will be predicted by baseline PET, with 
amyloid and tau having stronger predictive power in controls than metabolism, and that all 
three PET imaging agents will be predictive in MCI, with tau the most predictive. Finally, 
we predict that in all groups except AD, individuals with more brain amyloid will have more 
tau in the neocortex and that longitudinally, those with amyloid will show increases in 
neocortical tau over time.
2.8.1. Assessment of the contribution of non-AD pathology—We predict that 
hypoperfusion, altered diffusion, and atrophy on structural MRI will predict concurrent tau 
PET ligand uptake, and that the severity of cerebrovascular disease and cerebral microbleeds 
will modify the ability of MRI and other modalities to predict future cognitive decline. In 
combination with PET, biofluids, and clinical measures, we will operationalize the 
definitions of subgroups within the ADNI population. Formal definitions of groups like 
SNAP (suspected non-Alzheimer’s pathophysiology) [80, 81] and cerebrovascular 
phenotypes are needed to accommodate the biological heterogeneity within clinical trials 
populations. We anticipate that the development of new/optimized analysis methods and the 
creation of “AD-signature” summary numeric measures for each MR modality, and the 
optimization of inclusion/stratification, outcome metrics, and trial design will lower sample 
sizes and increase power of clinical trials.
2.9. Informatics Core
The Informatics Core, led by Arthur Toga, will continue to provide an information 
infrastructure to support the operational and research aims of each of the ADNI Cores and to 
provide data access and information resources for the wider research community. All new 
data acquired and produced as part of ADNI-3 will be stored in the Informatics Core ADNI 
repository at the Laboratory of Neuroimaging (LONI) at the University of Southern 
California. Data across all ADNI phases and data sources will be harmonized to enable 
coherent search functionality for interested investigators, and visualization on an interactive 
data platform. ADNI-3 data along with previous ADNI data will be provided in an ‘analysis-
ready‘ form for searching and downloads. They will also be provided for data aggregation 
efforts such as the Global Alzheimer’s Association Interactive Network.
3. Conclusions
ADNI-3 is poised to make substantial contributions to the improvement of clinical trials for 
AD therapies through the use of a variety of innovative approaches that build on the basis of 
knowledge accumulated in the study over the last 12 years. Recent results with tau PET 
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suggest that increased misfolded or aggregated tau levels and brain (which occurs in concert 
with reduced levels of soluble brain tau [82] correlate with cognition, correlate with CSF tau 
levels, correlate with the presence of amyloidosis and show longitudinal progression. Thus 
tau PET is a promising biomarker to track change and treatment effects. Tau PET may also 
demonstrate the features required to serve as a surrogate marker in AD treatment trials, 
greatly reducing the number of subjects and length of trials. The development of the 
Centiloid approach for comparing amyloid tracers will facilitate use of multiple amyloid 
PET tracers for diagnosis and clinical trial enrollment. Use of the new automated Roche 
immunoassay platform by the Biomarker Core may reduce the previous variance problems 
with CSF measurements of Aβ1–42 and tau/p-tau181. The Brain Health Registry will 
facilitate recruitment of characterized participants for ADNI-3, and provide at home 
assessments. ADNI-3 will be augmented by the addition of MRI imaging techniques that 
target structural and functional connectivity in the brain and allow sub-regional examination 
of the medial temporal lobe. A Systems Biology approach promises to uncover novel genetic 
contributions to AD that may be used for subject selection or enrichment. Continuation of 
the longitudinal phenotyping across all stages of the disease process, and with the inclusion 
of tau imaging and connectivity analyses will provide further insights into AD 
pathophysiology. Therefore, the innovative approach of ADNI-3 will facilitate the validation 
of biomarkers for AD trials, enabling development of effective preventive or disease-
modifying treatments for AD. Ultimately, we hope to build models that enable the 
implementation of precision medicine approaches to stratifying patients for clinical trials 
and therapy including combination therapy [83, 84].
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Research in context
1. Systematic review: The authors reviewed literature pertaining to the 
achievements of ADNI and the development of future methodologies for the 
ADNI-3 study using traditional sources such as PubMed. Extensive literature 
supports the widespread impact of the ADNI study in multiple areas and 
particularly in the improvement of clinical trials such as the ongoing A4 and 
A5 studies
2. Interpretation: Results from analysis of ADNI-1 and ADNI-2 data combined 
with latest advances in technology have informed the structure and approach 
of the upcoming ADNI-3 study.
3. Future directions: innovative technologies such as longitudinal tau imaging, 
MRI connectivity analyses, and a mass spectroscopy approach to biomarker 
analysis, in addition to the standardization of amyloid PET scanning using the 
Centiloid method, and continued multimodal analysis will be employed to 
further understand AD pathophysiology and disease progression. The Brain 
Health Registry will help recruit subjects and monitor their cognition.
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Figure 1. In-vivo Braak staging
Braak staging of healthy young adults (YA, n=5), healthy older adults (OA, n=15) and AD 
patients (n=15) based on AV-1451 Braak region of interest uptake, with participant 
characterization by in-vivo assigned Braak stage. ICV, intracranial volume. Values for Mini 
Mental State Exam (MMSE), Pittsburgh compound B distribution volume ratio (PIB DVR) 
index, and hippocampal volume are mean (SD). Reproduced with permission from [65].
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Figure 2. Comparison of Aβ1–42 results (pg/mL) for 10 patient CSF samples
UGOT, University of Gothenburg; UPENN, University of Pennsylvania. Each laboratory 
used their multiple reaction monitoring/tandem mass spectrometry method [72, 85], each 
approved by the Joint Committee for Traceability in Laboratory Medicine as reference 
methods.
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Table 1
Enrollment Plan
Rollover
(enrolled YR01)
New
(enrolled YR01)
New
(enrolled YR02) Total
Normal cognition (CN) 295 65 68 428
Amnestic MCI 274 65 86 425
AD 128 17 70 215
Total 697 147 224 1,068
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Table 2
MRI sequences in ADNI-3
Modality System Measures Notes
3D T1 volume MPRAGE – Siemens/Phiips 
IRFSPGR – GE
Structural changes Approximate 1mm3 resolution
3D-FLAIR All Cerebral microbleeds As in ADNI-2
Diffusion MRI Advanced if available or 
basic
WM tract geometry Similar to Human Connectome Project
Task-free fMRI Advanced if available or 
basic
Functional connectivity Similar to Human Connectome Project
Arterial Spin Labeling Capable systems Whole brain cerebral blood 
flow
Follows recommendations of ISMRM 
Perfusion Study Group and the European 
Consortium for ASL in Dementia [86].
Coronal high resolution T2 All MTL subregion analysis
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